Comparison of Fibrosis-4 with FibroScan for Liver Fibrosis Assessment in Non-Alcoholic Fatty Liver Disease Patients: A Cross-sectional Study
Keywords:
Aspartate Aminotransferases, Alanine, Fibrosis, Liver Cirrhosis, Non Alcoholic Fatty Liver Disease, TransaminaseAbstract
Objective: To compare the efficacy and accuracy of the Fibrosis-4 (FIB-4) index with FibroScan in assessing liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).Methods: This cross-sectional study was conducted at Patel Hospital, Karachi, Pakistan, from October 2023 to April 2024. All known cases of NAFLD or non-alcoholic steatohepatitis (NASH) aged ≥18 years, regardless of gender, were included. FIB-4 scores were measured using age, platelet level, aspartate transaminase (AST), and alanine transaminase (ALT). FibroScan categorized liver fibrosis into stages F0 to F4 with specific stiffness ranges: F0 (1–6 kPa), F1 (6.1–7 kPa), F2 (7.1–9 kPa), F3 (9.1–10.3 kPa), and F4 (≥10.4 kPa).Results: Of the 146 patients, the median age was 52.00 (IQR: 47.00–54.00) years. Based on FibroScan results, 61 (41.8%) patients were classified as F1, 35 (24.0%) as F2, 30 (20.5%) as F3, and 20 (13.7%) as F4. The diagnostic performance of FIB-4 showed an area under the curve of 0.83 (95% CI: 0.76–0.90). The optimal cut-off for FIB-4 was 1.28 with sensitivity, specificity, positive predictive value, negative predictive value, and overall diagnostic accuracy of 98.0%, 65.6%, 59.7%, 98.4%, and 76.7%, respectively. Spearman's correlation test (ρ) was applied and a significantly moderate correlation was found between FibroScan and FIB-4 (ρ = 0.50, p < 0.001).Conclusion: FIB-4 demonstrated higher accuracy and diagnostic performance in determining liver fibrosis in NAFLD patients compared to FibroScan.
Downloads
References
Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J 2019; 95:314-22. doi:10.1136/postgradmedj-2018-136316
Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016; 17:774. doi:10.3390/ijms17050774
Sivell C. Nonalcoholic fatty liver disease: a silent epide-mic. Gastroenterol Nurs 2019; 2:428-34. doi:10.1097/SGA.0000000000000443
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18:223-38. doi:10.1038/s41575-020-00381-6
Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev 2018; 2018:9547613. doi:10.1155/2018/9547613
Guo Y, Yang J, Ma R, Zhang X, Guo H, He J, et al. Metab-olic dysfunction-associated fatty liver disease is associated with the risk of incident cardiovascular disease: a prospective cohort study in Xinjiang. J Nutr 2022; 14:2361. doi:10.3390/nu14122361
Mumtaz S, Schomaker N, Von Roenn N. Pro: Noninvasive imaging has replaced biopsy as the gold standard in the evaluation of nonalcoholic fatty liver disease. Clin Liver Dis 2019; 13:111-3. doi:10.1002/cld.750
Malekzadeh R, Poustchi H. Fibro Scan for assessing liver fibrosis: An acceptable alternative for liver biopsy. Hepat Mon 2011; 11:157-8.
Fallatah HI, Akbar HO, Fallatah AM. Fibro scan compared to Fib-4, APRI, and AST/ALT ratio for assessment of liver fibrosis in Saudi patients with nonalcoholic fatty liver disease. Hepat Mon 2016; 16:e38346. doi:10.5812/hepatmon.38346
Cox BD, Trasolini R, Galts C, Yoshida EM, Marquez V. A18 8 COMPARING the performance of fibrosis-4 (fib-4) and non-alcoholic fatty liver disease fibrosis score (nfs) with fibro scan scores in non-alcoholic fatty liver disease. J Can Assoc Gastroenterol 2020; 3:59–60. doi:10.1093/jcag/gwz047.187
Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, et al. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017; 11:286-91. doi:10.1007/s12072-017-9796-z
Lazarus JV, Colombo M, Cortez-Pinto H, Huang TT, Mil-ler V, Ninburg M, et al. NAFLD - sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol 2020; 17:377-9. doi:10.1038/s41575-020-0315-7
Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, AP-RI, and AST/ALT ratio compared to Fibro Scan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021; 21:453. doi:10.1186/s12876-021-02038-3
Parkash O, Hamid S. Are we ready for a new epidemic of under recognized liver disease in South Asia especially in Pakistan? Non alcoholic fatty liver disease. J Pak Med Assoc 2013; 63:95.
Shah AS, Khan S, Rahim H, Chishti KA, Khan AG. Prevalence of non alcoholic fatty liver and non alcoholic steatohepatitis in Peshawar cantonment, Khyber Pakhtunkhwa, Pakistan. Pak J Pharm Sci 2018; 31:193-9.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24:908-22. doi:10.1038/s41591-018-0104-9
Badawi R, Hussein BE, Watany MM, Elsabagh HM, Elkha-lawany W. Fibrofast and Fibrosis-4 versus Fibro Scan as Indicators of Hepatic Fibrosis in Non Alcholic Fatty Liver Disease Patients: A Cross-Sectional Study. Afr J Gastroenterol Hepatol 2022; 5:58-75. doi:10.21608/ajgh.2022.153872.1010
Ding Y, Wang Z, Niu H, Deng Q, Wang Y, Xia S. FIB-4 is closer to Fibro Scan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning. Medicine (Baltimore) 2023; 102:e34957. doi:10.1097/MD.0000000000034957
Biberci Keskin E, Coban G. Evaluation of liver biopsy findings and comparison with noninvasive fibrosis scores in patients with non-alcoholic steatohepatitis. Medeni Med J 2019; 34:354–9 doi:10.5222/MMJ.2019
Khan SA, Yasmeen S, Adel H, Adil SO, Huda F, Khan S. Sonographic evaluation of normal liver, spleen, and renal parameters in adult population: a multicenter study. J Coll Physicians Surg Pak 2018; 28:834-9. doi:10.29271/jcpsp.2018.11.834
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fahad kakar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
